1. Introduction

Biotech ESG litigation risks are the legal risks faced by biotechnology companies, pharmaceutical manufacturers, genetic-engineering businesses, biosimilar developers, life-sciences research institutions and biotechnology investors arising from their environmental, social and governance (ESG) impacts, representations, disclosures and corporate conduct.

ESG litigation is particularly important in biotechnology because these businesses may deal with hazardous biological materials, genetically modified organisms (GMOs), clinical-trial participants, genetic information, pharmaceutical waste, complex supply chains and technologies that can affect human health and biodiversity.

Unlike ordinary environmental litigation, ESG litigation can also challenge whether a company accurately reported its environmental performance, respected patient rights, treated workers fairly, managed conflicts of interest or properly supervised its subsidiaries.

The Indian legal framework already provides potential routes for ESG-related claims through environmental law, constitutional principles, securities regulation, consumer protection, corporate governance and product-liability rules. An International Bar Association analysis published in October 2025 identifies greenwashing, climate-related claims, disclosure disputes and governance failures as important categories of ESG litigation in India.

International Bar Association+1

Important distinction: “Biotech ESG litigation” is a descriptive category, not a separate, universally recognised cause of action. The applicable claim depends on the facts, jurisdiction, statute and evidence. The cases discussed below include directly relevant biotechnology and pharmaceutical decisions as well as broader ESG precedents that may be applied by analogy.

2. The three pillars of biotech ESG litigation

バイオテクノロジーセンター（ドイツ製造拠点） | ロシュ・カスタムバイオテック（診断薬・医薬品原料事業） - ロシュ・ダイアグノスティックス株式会社

E — Environmental risks

Litigation concerning pharmaceutical effluent, hazardous laboratory waste, emissions, water contamination, biodiversity loss, GMO release, energy consumption and unsupported environmental claims.

Potential claimants: Regulators, affected communities, environmental organisations, investors and consumers.

Essential Guide to Research Ethics in Medical Research fo...

S — Social risks

Disputes involving clinical-trial consent, patient safety, genetic-data privacy, access to essential medicines, discrimination, labour conditions, research ethics and supply-chain human rights.

Potential claimants: Patients, trial participants, employees, consumers, communities and data subjects.

Pharmaceutical Training Solutions — Compliance eLearning | SHIFT

G — Governance risks

Misleading ESG disclosures, inaccurate sustainability reports, inadequate board oversight, regulatory non-disclosure, conflicts of interest, weak internal controls and improper executive incentives.

Potential claimants: Shareholders, regulators, lenders, contractual counterparties and, where legally permitted, other stakeholders.

These pillars frequently overlap. For example, pharmaceutical pollution is an environmental problem, but failure to disclose a material pollution-related shutdown can become a governance and securities-disclosure issue as well.

3. Major categories of litigation risk

A. Environmental pollution and hazardous waste

Biotechnology and pharmaceutical manufacturing may generate chemical waste, biologically contaminated materials, solvents, effluent and other hazardous substances. Improper treatment, storage or disposal may cause environmental damage and expose a company to regulatory action, remediation orders, compensation claims or criminal proceedings where statutory requirements are met.

Principal Indian laws potentially involved include:

Environment (Protection) Act, 1986.

Water (Prevention and Control of Pollution) Act, 1974.

Air (Prevention and Control of Pollution) Act, 1981.

Hazardous and Other Wastes (Management and Transboundary Movement) Rules, 2016.

Biomedical Waste Management Rules, 2016, where the waste falls within their scope.

Applicable consent, environmental-clearance and biotechnology-safety requirements.

Illustration: A biologics manufacturer advertises that its plant has zero untreated discharge, but inspections reveal that untreated effluent has entered a local waterway. The company may face pollution-control proceedings, environmental compensation, restoration obligations and potential claims arising from inaccurate ESG disclosures.

B. Climate-related claims and greenwashing

Greenwashing occurs when a company makes environmental or sustainability claims that are false, materially misleading, insufficiently substantiated or presented without important qualifications.

Examples include claims that:

A biologic medicine is “carbon neutral” without a defensible basis.

Packaging is “fully biodegradable” despite significant disposal limitations.

Manufacturing is “zero waste” while substantial hazardous waste is generated.

A company has achieved a net-zero target without a credible implementation plan.

A product reduces environmental impacts without adequate comparative evidence.

Potential causes of action include securities fraud or disclosure violations, consumer-protection claims, misleading-advertising proceedings and contractual misrepresentation, depending on the jurisdiction and facts.

The litigation risk is not limited to false statements. A company may also face scrutiny for omitting material qualifications, failing to explain how offsets work or presenting an aspirational target as an accomplished result.

American College of Cardiology+1

C. Genetically modified organisms and biodiversity

Companies involved in gene editing, agricultural biotechnology, synthetic biology and engineered microorganisms may face disputes about environmental release, ecological risks, biosafety assessments, regulatory approval and public consultation.

Risks include:

Allegedly inadequate environmental-risk assessments.

Failure to comply with approval conditions.

Unauthorised release or transfer of genetically modified organisms.

Potential harm to non-target organisms or biodiversity.

Disputes concerning public participation and regulatory transparency.

Challenges to government decisions authorising a genetically modified product.

A crucial legal distinction is that a scientific disagreement about a GMO does not automatically establish illegality. A claimant ordinarily needs to identify an applicable legal requirement, procedural defect, evidentiary deficiency or legally cognisable environmental risk.

D. Clinical trials, patient safety and informed consent

Biotech firms may face claims concerning inadequate informed consent, undisclosed trial risks, adverse events, research misconduct, protocol violations and failures to protect vulnerable participants.

Relevant Indian legal frameworks can include the New Drugs and Clinical Trials Rules, 2019, the Drugs and Cosmetics Act, 1940, applicable ethics-committee requirements, and constitutional or civil-law remedies where available.

Potential consequences include suspension of trials, regulatory sanctions, compensation obligations, loss of research partnerships and reputational damage.

E. Genetic data, privacy and discrimination

Genomic and other biological data can reveal highly sensitive information about an individual and their relatives. Litigation risks may arise from unauthorised collection, secondary use, disclosure, inadequate security or discriminatory use of genetic information.

Depending on the facts, applicable law may include India's Digital Personal Data Protection Act, 2023, once and to the extent its relevant provisions are in force, together with other applicable privacy, contractual, medical-confidentiality and sectoral requirements.

Potential disputes may involve data subjects, research participants, employees, patients or commercial partners. Companies should not assume that anonymisation eliminates every risk of re-identification or that consent for one research purpose automatically permits every subsequent use.

F. Supply-chain responsibility and human rights

Biotechnology companies often rely on contract manufacturers, clinical-research organisations, agricultural suppliers, raw-material producers and overseas subsidiaries. ESG claims may arise when those partners are associated with unsafe working conditions, forced labour, inadequate safety controls or environmental violations.

The central questions include:

Did the company know, or should it reasonably have identified, the relevant risk?

Did it exercise the oversight required by applicable law or contract?

Did it make accurate statements about supplier audits and ethical sourcing?

Does the relevant jurisdiction permit claims against a parent company for the conduct of a subsidiary or supplier?

Parent-company liability is not automatic merely because the parent owns a subsidiary. Actual control, assumed responsibilities, applicable duties and the evidence connecting the parent to the alleged wrongdoing can be decisive.

G. Governance, board accountability and disclosure failures

Governance litigation may target directors, officers or the company where material ESG information is misstated, omitted or inadequately supervised.

Common triggers include:

Failure to disclose significant pollution incidents or regulatory action.

Inaccurate Business Responsibility and Sustainability Reporting (BRSR).

Unsupported claims in annual reports, investor presentations or public statements.

Weak internal reporting and escalation mechanisms.

Conflicts of interest in clinical research or procurement.

Failure to investigate known compliance breaches.

In India, section 166(2) of the Companies Act, 2013, requires directors to act in good faith in the interests of the company, its employees, shareholders, community and the protection of the environment. Section 135 establishes CSR obligations for companies meeting the applicable statutory thresholds. These provisions have distinct purposes: CSR expenditure is not a substitute for environmental compliance, and neither provision automatically creates liability for every ESG shortcoming.

International Bar Association+1

4. Important case laws and their legal principles

The following cases are especially useful for understanding the litigation exposure of biotech and pharmaceutical companies. Some directly concern biotechnology or pharmaceutical operations; others establish principles relevant to ESG disclosures and corporate accountability.

Case 1: Alembic Pharmaceuticals Ltd. v. Rohit Prajapati

Supreme Court of India · 2020 · Civil Appeal No. 1526 of 2016 and connected appeals

Facts: Pharmaceutical and chemical industries in Ankleshwar, Gujarat, had operated without the required prior environmental clearance. A government circular permitted ex post facto environmental clearance in the circumstances at issue.

Issue: Could the regulatory framework retrospectively regularise industrial operations that had begun without the required prior environmental clearance?

Decision: The Supreme Court rejected the legality of the circular permitting the relevant ex post facto clearances. It directed the industries concerned to pay ₹10 crore each for environmental restoration, while not ordering their closure in the particular disposition.

Sci API+1

ESG significance:

Environmental clearance must be addressed before covered operations begin.

A company cannot safely treat later regulatory approval as a routine substitute for prior compliance.

Environmental violations can lead to substantial financial consequences and remedial orders.

ESG reporting should accurately disclose the status of environmental permissions and material non-compliance.

Application to biotechnology: A biologics facility that starts production or expands a regulated project without required prior clearance may face analogous regulatory and environmental litigation. Whether a particular biotechnology facility requires environmental clearance depends on the applicable notification, activity and facts.

Case 2: TestBioTech eV v. European Commission

General Court of the European Union · Case T-33/16 · 14 March 2018

Facts: TestBioTech challenged the European Commission's refusal to conduct an internal review of decisions authorising the placing on the market of certain genetically modified soybeans.

Issue: Could GMO authorisation decisions be reviewed through the environmental-law mechanisms available under the EU's Aarhus Convention implementation framework?

Decision: The General Court annulled the Commission's refusal. It held that the relevant GMO authorisation decisions fell within the environmental-law framework for internal review. The ruling concerned access to review, rather than a definitive finding that the authorised soybeans were unsafe.

EUR-Lex+1

ESG significance:

GMO regulatory decisions may be subject to environmental scrutiny.

Environmental organisations can have procedural routes to challenge certain administrative decisions.

Scientific assessment, transparent reasoning and a legally adequate review process are important to biotechnology governance.

Application to biotechnology: Companies seeking GMO approvals in the EU should ensure that risk assessments, supporting evidence and regulatory submissions are robust enough to withstand scrutiny and potential review proceedings.

Case 3: Swanson v. Danimer Scientific, Inc.

United States · Second Circuit · dismissal affirmed in 2024

Facts: Investors alleged that Danimer Scientific, a manufacturer of biodegradable bioplastics, had made misleading statements concerning the environmental characteristics of its products. The litigation included allegations about biodegradation in landfill conditions.

Decision: The Second Circuit affirmed dismissal of the securities-fraud action in a summary order, finding the allegations insufficient to plead the required scienter against the defendants.

The Climate Litigation Database+1

ESG significance:

Environmental claims may generate securities litigation when investors allege material misrepresentations.

Scientific criticism of a product does not, by itself, establish securities fraud.

A claimant must satisfy the applicable pleading requirements, including the relevant mental-state requirement where required.

Application to biotechnology: A company selling bioengineered materials, sustainable packaging or low-carbon bioproducts should substantiate environmental claims with appropriate testing and clearly explain the conditions under which its claims hold true.

This case illustrates that ESG litigation is not automatically successful merely because an environmental claim is disputed.

Case 4: M.C. Mehta v. Union of India

Supreme Court of India · (1987) 1 SCC 395

Facts: The litigation arose from the escape of oleum gas from an industrial unit in Delhi and the resulting public-safety concerns.

Legal principle: The Supreme Court developed the doctrine of absolute liability for enterprises engaged in hazardous or inherently dangerous activities, subject to the scope of the doctrine as developed in Indian law.

ESG significance:

Hazardous industrial activities may attract stringent liability principles.

Companies cannot assume that ordinary negligence standards will always define their exposure.

Safety systems, incident prevention, emergency response and remediation are central to risk management.

Application to biotechnology: Where a biotech or pharmaceutical operation qualifies as hazardous or inherently dangerous under the applicable law, serious accidents involving toxic chemicals or dangerous biological materials may raise questions about stringent enterprise liability. The doctrine does not mean that every laboratory incident automatically attracts absolute liability.

Case 5: Indian Council for Enviro-Legal Action v. Union of India

Supreme Court of India · (1996) 3 SCC 212

Facts: Industrial chemical pollution in Rajasthan caused significant environmental harm, prompting proceedings seeking remediation and accountability.

Legal principle: The Supreme Court reinforced the polluter-pays principle, under which polluting industries may be required to bear the costs of remedying environmental damage.

ESG significance:

Environmental costs may extend beyond fines to restoration and remediation.

Corporate budgeting should account for environmental liabilities, not just ordinary compliance expenses.

Pollution may create long-term financial, operational and reputational risks.

Application to biotechnology: Pharmaceutical effluent, hazardous-waste contamination and other industrial pollution may expose a company to restoration costs where the relevant legal conditions are satisfied.

Case 6: Vellore Citizens’ Welfare Forum v. Union of India

Supreme Court of India · (1996) 5 SCC 647

Facts: Tannery pollution in Tamil Nadu damaged water resources and agricultural land.

Legal principle: The Court recognised the precautionary principle and polluter-pays principle as essential features of Indian environmental law.

ESG significance:

Scientific uncertainty does not necessarily justify ignoring a serious environmental risk.

Preventive controls and environmental monitoring can be legally important.

Companies may need to adopt safeguards proportionate to the risks of their activities.

Application to biotechnology: A company planning a new biological process or industrial discharge should assess credible environmental risks in advance, particularly where contamination could be difficult to reverse.

Case 7: A.P. Pollution Control Board v. Prof. M.V. Nayudu

Supreme Court of India · (1999) 2 SCC 718

Legal principle: The Supreme Court examined the relationship between scientific uncertainty, environmental decision-making and the precautionary principle, emphasising the importance of sound scientific expertise in complex environmental disputes.

ESG significance: Biotechnology litigation often depends on specialised scientific evidence. Courts and regulators may have to assess disputed toxicology, biological safety, ecological impacts and technical risk assessments.

Application to biotechnology: Maintaining traceable scientific records, independent validation, documented assumptions and reliable expert evidence can be important when a regulatory decision or environmental claim is challenged.

Case 8: Piramal Enterprises / Piramal Pharma ESG disclosure proceedings

SEBI proceedings · Reported in November 2024

Background: The dispute concerned allegations of non-disclosure relating to environmental action against a pharmaceutical business. Reporting described an ₹8.32 crore National Green Tribunal penalty concerning water pollution and an alleged failure to disclose a plant closure ordered by the Telangana State Pollution Control Board.

Outcome: According to the reported account, SEBI exonerated Piramal Pharma in the non-disclosure matter because the regulator had not established the materiality of the information alleged to have been omitted.

Regstreet Law Advisors

ESG significance:

Not every environmental violation necessarily constitutes a securities-disclosure violation.

Materiality and the applicable disclosure requirements must be established.

Corporate reorganisations and demergers can complicate responsibility for historical environmental liabilities and disclosure obligations.

Application to biotechnology: Companies should document how they determine whether a pollution incident, regulatory order, clinical suspension or facility shutdown is material to investors. This reported regulatory outcome should not be treated as a general exemption from environmental or disclosure obligations.

5. Indian regulatory framework for biotech ESG litigation

SEBI's 2023 BRSR Core framework introduced a structured set of ESG indicators and an assurance framework, with phased applicability. Its original schedule covered the top 150 listed entities in FY 2023–24, top 250 in FY 2024–25, top 500 in FY 2025–26 and top 1,000 in FY 2026–27. Companies should verify the current consolidated requirements and subsequent amendments before determining their obligations.

1689166456465.pdf+1

The key point is that ESG reporting creates an evidentiary trail. A sustainability statement may later be compared with pollution-control records, internal audits, clinical-trial data, regulatory correspondence and actual operating performance.

6. How ESG litigation can arise: a practical example

Consider a hypothetical Indian biotechnology company that manufactures an engineered therapeutic protein.

Stage 1 — Environmental breach

The company improperly discharges manufacturing waste into a waterway.

Stage 2 — Regulatory enforcement

Pollution-control authorities investigate, impose restrictions or initiate proceedings under applicable environmental legislation.

Stage 3 — Disclosure risk

The company publishes a sustainability report claiming that all wastewater is treated and all regulatory requirements are met.

Stage 4 — Multiple legal exposures

Depending on the facts, the company may face environmental proceedings, investor claims, regulatory disclosure action and consumer or contractual disputes.

The same facts can generate several distinct legal proceedings. However, each claim must independently satisfy its legal requirements; an environmental violation does not automatically prove fraud, and an inaccurate ESG statement does not automatically establish that every director is personally liable.

7. Who can bring ESG-related proceedings?

8. Principal legal consequences

A biotech company facing ESG litigation may incur:

Financial liability: Damages, environmental compensation, remediation costs, penalties and legal expenses.

Operational restrictions: Plant closures, suspension of activities, withdrawal of approvals or corrective directions where authorised.

Securities exposure: Regulatory action or investor litigation concerning materially misleading disclosures.

Director and officer exposure: Potential personal liability where statutory duties, participation, knowledge or other applicable requirements are established.

Commercial consequences: Loss of licences, research partnerships, procurement contracts, funding or insurance coverage.

Reputational harm: Reduced public trust, patient confidence and investor support.

Cross-border exposure: Proceedings in more than one jurisdiction where operations, securities offerings, data processing or regulatory duties span borders.

The extent of liability depends on the governing law, evidence, procedural rules and remedies available in the particular case.

9. Risk-prevention and compliance framework

A biotech business can reduce exposure through a coordinated ESG compliance programme.

Environmental controls

Maintain valid permits, monitor effluent and emissions, audit hazardous-waste disposal, document GMO safeguards and maintain incident-response procedures.

Scientific substantiation

Support biodegradability, carbon-neutrality, sustainability and product-safety claims with appropriate data, transparent methodologies and clearly stated limitations.

Accurate disclosures

Reconcile sustainability reports with regulatory filings, facility records, litigation, material incidents and internal audit findings.

Clinical and patient safeguards

Maintain valid consent processes, ethics oversight, adverse-event reporting and documented research protocols.

Privacy and cybersecurity

Implement access controls, data minimisation, security testing, incident response and lawful governance of genomic and clinical data.

Supply-chain due diligence

Assess contract manufacturers and suppliers, preserve audit rights, investigate red flags and establish corrective-action procedures.

Board oversight

Assign clear responsibility for ESG metrics, require periodic risk reviews and ensure material issues are escalated to the board.

Independent assurance

Use competent and sufficiently independent assurance providers, with controls to prevent conflicts of interest.

For Indian listed companies, these controls should be aligned with the applicable SEBI BRSR and BRSR Core requirements, including relevant assurance and value-chain reporting obligations.

1689166456465.pdf+2

10. Critical legal issues for further research

Several unresolved or fact-sensitive issues deserve particular attention:

Greenwashing liability: When does an aspirational sustainability commitment become a legally actionable misrepresentation?

Scientific uncertainty: What quality of evidence is sufficient to establish environmental harm or an inadequate biosafety assessment?

Director accountability: When does inadequate ESG oversight amount to a breach of a statutory or fiduciary duty?

Genetic privacy: How should consent, data security, secondary research and familial genetic information be reconciled?

Corporate-group responsibility: When can a parent company be liable for environmental or human-rights harms connected to overseas operations?

Materiality: When must pollution, clinical-trial problems or regulatory sanctions be disclosed to investors?

Access to justice: What procedural rights do affected communities and environmental organisations have when challenging biotechnology approvals?

These questions should be examined using the relevant statute and jurisdiction-specific authorities rather than assuming that a single universal ESG doctrine applies.

Conclusion

Biotech ESG litigation sits at the intersection of environmental protection, human rights, scientific regulation, corporate governance and investor disclosure. The principal legal risk is not simply that a company fails to meet a sustainability target; it is that the underlying conduct violates applicable law, harms stakeholders or is inaccurately represented to regulators, investors, patients or the public.

The Indian Supreme Court's decisions in Alembic Pharmaceuticals, M.C. Mehta, Indian Council for Enviro-Legal Action and Vellore Citizens’ Welfare Forum, together with the EU's TestBioTech judgment and the US Swanson v. Danimer Scientific litigation, illustrate different parts of this legal landscape.

The most defensible strategy is to combine scientifically supportable ESG claims, rigorous regulatory compliance, documented board oversight, transparent reporting and effective stakeholder safeguards.

Legal note: This is an educational overview, not jurisdiction-specific legal advice. Case descriptions are summaries, and the current status of relevant statutes, regulations, judgments and subsequent appeals should be verified before relying on them in a legal submission.